Author: admin

“Rheumatoid Arthritis Clinical Trials”

(Albany, USA) “Rheumatoid Arthritis Pipeline Insight 2025” report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Rheumatoid Arthritis Market.

Rheumatoid Arthritis pipeline report including 75+ key companies and 80+ Rheumatoid Arthritis treatment therapies, analyses DelveInsight. Rheumatoid Arthritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

To know more about the Rheumatoid Arthritis Pipeline Analysis, click here: Rheumatoid Arthritis Pipeline Insight

Some of the key takeaways from the Rheumatoid Arthritis Pipeline Report:

• Rheumatoid Arthritis Companies across the globe are diligently working toward developing novel Rheumatoid Arthritis treatment therapies with a considerable amount of success over the years.
• Rheumatoid Arthritis companies working in the treatment market are Taisho Pharmaceutical, Zhejiang Hisun Pharmaceutical, SinoMab, Jiangsu Hengrui Medicine, RemeGen, GlaxoSmithKline, Modern Biosciences, Jiangsu Alphamab Biopharmaceuticals, Akros Pharma, Hanlim Pharm, Galapagos NV, Chong Kun Dang Pharmaceutical, Bristol Myers Squibb, AstraZeneca, Aclaris Therapeutics, Abivax, AbbVie, Synact Pharma, Gilead sciences, Mesoblast, Rottapharm Biotech, Eli Lilly and Company, Kiniksa Pharmaceuticals, Abcentra, Cyxone, Yungjin Pharm. Co., Ltd. Taiho Pharmaceutical, Oscotec Inc., Pfizer, Janssen Research & Development, Cipher Pharmaceuticals Inc., KLUS Pharma Inc., Revolo Biotherapeutics, Lynk Pharmaceuticals, Beijing Baylx Biotech, Hope Biosciences, Kangstem Biotech, Celltex Therapeutics, I-Mab Biopharma Co. Ltd., Synermore Biologics Co., Ltd, Oryn Therapeutics, Arthrogen, Bayer, Amgen, Draconis Pharma, Biozeus, Landos Biopharma, Imcyse, Kymera Therapeutics, RedHill Biopharma, 4D Pharma, CV6 Therapeutics, VYNE Therapeutics, MyMD Pharmaceuticals, Brickell Biotech Inc, Worg Pharmaceuticals, Almirall, Standigm, Metrion Biosciences, Jnana Therapeutics, Silo Pharma, SFA Therapeutics, Neutrolis Therapeutics, Ahead Therapeutics, Fresenius Kabi, Kidswell Bio, BioXpress Therapeutics, CinnaGen, Alvotech, Hetero Biopharma, Shanghai Henlius Biotech, Cadila Pharmaceuticals, Innovent Biologics, Torrent Pharmaceuticals, Emcure Pharmaceuticals, mAbxience, Shanghai Junshi Biosciences, Enosi Therapeutics, and others, are developing therapies for the Rheumatoid Arthritis treatment.
• Emerging Rheumatoid Arthritis therapies such as TS152, HS-016, SM03, SHR0302, RC18, Otilimab, NI-0101, MBS2320, KN019, JTE-051, Interleukin 2, HL237, GLPG3970, Elsubrutinib, CKD-506, Branebrutinib, AZD9567, ATI-450, ABX464, ABBV 3373, ABBV 154, AP1189, F8IL10, AMT-101, GS-9876, CR 6086, LY 3462817, KPL-404, Orticumab, Rabeximod, YRA 1909, VIB4920, Varicella Zoster Vaccine, TAS5315, SKI-O-703, SAN-300, PF-06650833, Nipocalimab, CF-101, A223, IRL 201805, LNK 01001, PRTX-100, hUC-MSC infusion, HB-adMSC, LABP-104, VAY736, TJ003234 , SYN060, GS-5718, PF-06835375, Nivolumab, MH004, ORTD-1, ART-I02, FB704A, Amilo 5MER, CKD-374 , CFZ-533, BAY 1830839, AMG 570, JNJ-4703, CT-P47, BZ068, Invossa, LABP-69, ICM-203-R, NX-5948, KT-474 , Clarithromycin/clofazimine/rifabutin (RHB-104), Research programme: small molecule TYK2 inhibitors, MRx0006, CV6 1271, VYN201, MYMD-1, BBI 02, Research Programme: Immune mediated diseases, Foralumab, SPU-21, SFA002, NTR-441, Research programme: autoimmune disease therapeutics, AT_1001, MSB11456, MabionCD20, DMB-3113, GB232, GBS 005, TX17, BX 2922, Cinnora, AVT02, MYL-1401A, and others are expected to have a significant impact on the Rheumatoid Arthritis market in the coming years.
• In July 2025, AbbVie conducted a study currently includes 3 substudies evaluating different treatments in participants with RA. Substudy 1 will evaluate lutikizumab monotherapy (treatment given alone) compared to placebo (looks like the study treatment but contains no medicine). Substudy 2 will evaluate ravagalimab monotherapy compared to placebo and Substudy 3 will evaluate lutikizumab and ravagalimab combination therapy (treatments given together) compared to placebo. Approximately 180 participants who have failed 1 or 2 biologic/targeted synthetic disease-modifying antirheumatic drug (tsDMARD) therapies will be enrolled in the study at approximately 65 sites worldwide.
• In June 2025, AnaptysBio, Inc. announced that investigational rosnilimab, a depleter and agonist targeting PD1+ T cells, demonstrated a best-in-disease profile in patients with moderate-to-severe rheumatoid arthritis (RA). In the robust, global 424-patient Phase IIb trial, rosnilimab achieved JAK-like efficacy on multiple clinically meaningful measures, including low disease activity (LDA) and remission on the Clinical Disease Activity Index (CDAI), as well as ACR70 response, over a six-month period.
• In March 2025, SynAct Pharma AB announced that the United States Patent and Trademark Office (USPTO) had issued US patent 12,239,631 with claims covering the crystal form of resomelagon (AP1189) currently undergoing development in clinical Phase IIb. The US patent is a major cornerstone in the strategy to further protect SynAct’s intellectual property rights with respect to resomelagon and will add to the layers of protection ensuring exclusivity in the US of its lead asset as composition of matter until 2042.
• On January 2024, Rise Therapeutics LLC announced results of a Single and Repeat Dosing Study of the Safety, Drug Exposure and Clinical Activity of R-2487 in Patients with Rheumatoid Arthritis.
• On March 2024, Sonoma Biotherapeutics, Inc announced results of a Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Activity of Single Ascending Doses of SBT777101 in Subjects with Rheumatoid Arthritis.
• On March 2024, Lynk Pharmaceuticals Co., Ltd announced results of a Randomized, Double-blind Study to Compare LNK01001 to Placebo in Adults with Rheumatoid Arthritis (RA) on a Stable Dose of csDMARDs Who Have an Inadequate Response or Intolerance to bDMARDs.
• On February 2024, Eli Lilly and Company announced results of an Adaptive Phase 2a/2b, Randomized, Double-Blind, Placebo-Controlled Study of LY3871801 in Adult Participants With Moderately-to-Severely Active Rheumatoid Arthritis.
• On April 2024, AbbVie announced results of a Phase 3b/4 Randomized, Double-Blind, Double Dummy, Active Comparator-Controlled Study, Comparing the Efficacy and Safety of Upadacitinib Versus Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis on a Stable Background of MTX and Who Had an Inadequate Response or Intolerance to a Single TNF Inhibitor (SELECT- SWITCH).
• On March 2024, AstraZeneca announced results of a Phase I, Randomised, Double-blind, Placebo-controlled, Single Ascending Dose Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Subcutaneous AZD6912 in Healthy Participants.

Rheumatoid Arthritis Overview:

Rheumatoid arthritis (RA) is a chronic autoimmune disorder that primarily affects the joints, causing inflammation, pain, stiffness, and potential joint damage and deformity over time. It occurs when the immune system mistakenly attacks the body’s own tissues, particularly the synovium—the lining of the membranes that surround the joints. Rheumatoid arthritis commonly affects smaller joints like those in the hands and feet, but it can also impact larger joints and other organs. Rheumatoid arthritis Symptoms often fluctuate in severity and can include fatigue, joint swelling, and reduced range of motion. Early Rheumatoid arthritis diagnosis and aggressive treatment are vital in managing Rheumatoid arthritis to slow disease progression, alleviate symptoms, and preserve joint function. Rheumatoid arthritis Treatment typically involves a combination of medications (such as disease-modifying anti-rheumatic drugs and biologics), physical therapy, lifestyle modifications, and sometimes surgery to repair or replace severely damaged joints.

Stay ahead with the most recent pipeline outlook for Rheumatoid Arthritis. Get insights into clinical trials, emerging therapies, and leading companies with Rheumatoid Arthritis @ Rheumatoid Arthritis Treatment Drugs and Manufacturers

Rheumatoid Arthritis Emerging Drugs Profile

• RGB-19: Gedeon Richter

RGB-19, developed by Gedeon Richter in collaboration with Mochida Pharmaceutical, is a biosimilar version of tocilizumab, a monoclonal antibody that inhibits interleukin-6 (IL-6) signaling, which plays a central role in the inflammation associated with rheumatoid arthritis. By targeting IL-6, RGB-19 aims to reduce inflammation and alleviate symptoms in patients with rheumatoid arthritis and other immune-mediated conditions. As a biosimilar to the reference product RoActemra®, RGB-19 is designed to offer comparable efficacy and safety, while providing a more affordable therapeutic option to patients worldwide, thereby expanding access to this important biological treatmentCurrently, the drug is registered for the treatment of Rheumatoid Arthritis (RA).

• MB04: mAbxience Research S.L.

MB04, developed by mAbxience Research S.L., is a biosimilar to etanercept designed for the treatment of rheumatoid arthritis and other autoimmune diseases. It is an Fc fusion protein that targets and inhibits both tumor necrosis factor alpha (TNF-α) and lymphotoxin alpha (LTα, also known as TNF-β), key cytokines involved in the inflammatory processes underlying rheumatoid arthritis. By blocking these cytokines, MB04 aims to reduce inflammation and alleviate symptoms associated with immune-mediated joint damage. As a biosimilar, MB04 is intended to offer comparable efficacy and safety to the reference biologic (Enbrel®), while potentially improving access and affordability for patients requiring long-term management of rheumatoid arthritis. Currently, the drug is in Phase III stage of its development for the treatment of Rheumatoid Arthritis (RA).

• Rosnilimab: AnaptysBio, Inc

Rosnilimab is a novel therapeutic antibody that directly targets PD-1, a co-inhibitory receptor preferentially expressed on the surface of activated T cells, which broadly impacts the pathogenic drivers of inflammatory diseases such as RA and UC. Rosnilimab is a targeted therapy designed to deplete PD-1high T cells and agonize the remaining PD-1+ T cells to restore the immune system back to a state of homeostasis. This is anticipated to result in specific immunological outcomes in both inflamed tissue and the periphery, such as reduction in T cell proliferation, migration and cytokine secretion, and reduction of plasma cell generation and autoantibody levels. Currently, the drug is in Phase II stage of its development for the treatment of Rheumatoid Arthritis (RA).

• Leramistat: Istesso

Leramistat is an oral treatment that selectively modulates inflammation at the level of tissue damage, adapting to stimulus strength. By avoiding outright inhibition of inflammatory cytokine cascades and promoting a pro-repair environment, leramistat fine-tunes control of subclinical inflammation and restores normal bone dynamics to resolve rheumatoid pathology at its source. With its unique “pro-repair” mechanism, leramistat offers a new foundational option for combination therapy, enabling other disease-modifying treatments to work better for longer and elevating the definition of remission. Currently, the drug is in Phase II stage of its development for the treatment of Rheumatoid Arthritis (RA).

• AP1189: Synact Pharma

SynAct Pharma’s drug candidate, resomelagon (AP1189), is a once-daily oral biased melanocortin receptor type 1 and 3 (MC1r and MC3r) agonist. The pharmacological effects of the compound are mediated by its ability to balance ongoing inflammation and bringing the immune system in a given inflamed tissue, organ, or circulation to a new homeostatic state with less proinflammatory activity and activation of pro-resolving pathways. This effect is distinct from suppression of the immune system, which may cause unwanted side effects, such as increased risk of infections and other side effects. The mode of action is specifically interesting to apply in active inflammation, including early active states of chronic inflammatory/autoimmune diseases and in hyperinflammatory states of infectious diseases where the benefit of applying immunosuppressive drugs is outweighed by the risk of use. The selectivity of resomelagon (AP1189) to MC1r and MC3r means that MC2r mediated glucocorticoid release from the adrenal gland is avoided. Thus, the compound induces its pharmacological effects in a steroid-free manner without the significant safety, tolerability, and side effect issues associated with adrenocorticotropic hormone (ACTH) based therapies. Further to that, the compound stimulates the MC1r through biased agonism, activating an alternative pathway, so the compound can be given without the unwanted side effect of skin hyperpigmentation that classical MC1r agonists will induce though cAMP activation in melanocytes. Currently, the drug is in Phase II stage of its development for the treatment of Rheumatoid Arthritis (RA).

• LPX-TI641: LAPIX Therapeutics

LPX-TI641 is an oral, small-molecule designed to bind the phosphatidylserine binding pocket on the T cell/transmembrane, immunoglobulin, and mucin (Tim) family of receptors. It is currently under clinical development for autoimmune indications such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and multiple sclerosis with plans to expand to other autoimmune indications where the underlying pathology involves immune imbalances and loss of self-tolerance. LPX-TI641’s primary pharmacology works to restore the adaptive immune system’s self-tolerance rather than suppressing immunity, enabling patients to more effectively and gently combat autoimmune disease. Toxicological studies and emerging clinical data show that LPX-TI641 does not induce neutropenia or lymphocytopenia, suggesting a potentially improved safety profile compared to current therapies. Currently, the drug is in Phase I stage of its development for the treatment of Rheumatoid Arthritis (RA).

DelveInsight’s Rheumatoid Arthritis Pipeline Drugs Report covers around 80+ products under different phases of clinical development like

• Late-stage Rheumatoid Arthritis products (Phase III)
• Mid-stage Rheumatoid Arthritis products (Phase II)
• Early-stage Rheumatoid Arthritis product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Rheumatoid Arthritis Route of Administration

Explore DelveInsight’s Rheumatoid Arthritis Pipeline Drugs Report featuring 80+ promising therapies across various stages of clinical development @ Rheumatoid Arthritis Medication and FDA Approvals

Emerging Rheumatoid Arthritis Drugs Under Different Phases of Clinical Development Include:

• TS152: Taisho Pharmaceutical
• SM03: SinoMab
• SHR0302: Jiangsu Hengrui Medicine
• RC18: RemeGen
• Otilimab: GlaxoSmithKline
• ATI-450: Aclaris Therapeutics
• MBS2320: Modern Biosciences
• PF-06651600: Pfizer
• Obefazimod: Abivax
• ABBV-154: AbbVie
• Branebrutinib: Bristol Myers Squibb
• KPL-404: Kiniksa Pharmaceuticals
• ORTD-1: Oryn Therapeutics
• MRx0006: 4D pharma plc.
• LABP-69: Landos Biopharma, Inc
• BZ068: Biozeus
• And Many Others.

Further Rheumatoid Arthritis product details are provided in the report. Download the Rheumatoid Arthritis report to learn more about the emerging Rheumatoid Arthritis therapies @ Rheumatoid Arthritis Drugs and Therapies

Rheumatoid Arthritis Pipeline Analysis

The Rheumatoid Arthritis pipeline report provides insights into:

• The report provides detailed insights about companies that are developing therapies for the treatment of Rheumatoid Arthritis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Rheumatoid Arthritis Treatment.
• Rheumatoid Arthritis key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Rheumatoid Arthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Rheumatoid Arthritis market.

The Rheumatoid Arthritis therapeutics report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Key companies in the Rheumatoid Arthritis Therapeutics Market:

Some of the Rheumatoid Arthritis Companies working in the market are Taisho Pharmaceutical, Zhejiang Hisun Pharmaceutical, SinoMab, Jiangsu Hengrui Medicine, RemeGen, GlaxoSmithKline, Modern Biosciences, Jiangsu Alphamab Biopharmaceuticals, Akros Pharma, Hanlim Pharm, Galapagos NV, Chong Kun Dang Pharmaceutical, Bristol Myers Squibb, AstraZeneca, Aclaris Therapeutics, Abivax, AbbVie, Synact Pharma, Gilead sciences, Mesoblast, Rottapharm Biotech, Eli Lilly and Company, Kiniksa Pharmaceuticals, Abcentra, Cyxone, Yungjin Pharm. Co., Ltd. Taiho Pharmaceutical, Oscotec Inc., Pfizer, Janssen Research & Development, Cipher Pharmaceuticals Inc., KLUS Pharma Inc., Revolo Biotherapeutics, Lynk Pharmaceuticals, Beijing Baylx Biotech, Hope Biosciences, Kangstem Biotech, Celltex Therapeutics, I-Mab Biopharma Co. Ltd., Synermore Biologics Co., Ltd, Oryn Therapeutics, Arthrogen, Bayer, Amgen, Draconis Pharma, Biozeus, Landos Biopharma, Imcyse, Kymera Therapeutics, RedHill Biopharma, 4D Pharma, CV6 Therapeutics, VYNE Therapeutics, MyMD Pharmaceuticals, Brickell Biotech Inc, Worg Pharmaceuticals, Almirall, Standigm, Metrion Biosciences, Jnana Therapeutics, Silo Pharma, SFA Therapeutics, Neutrolis Therapeutics, Ahead Therapeutics, Fresenius Kabi, Kidswell Bio, BioXpress Therapeutics, CinnaGen, Alvotech, Hetero Biopharma, Shanghai Henlius Biotech, Cadila Pharmaceuticals, Innovent Biologics, Torrent Pharmaceuticals, Emcure Pharmaceuticals, mAbxience, Shanghai Junshi Biosciences, Enosi Therapeutics, and others.

Request for Sample PDF Report to know in detail about Rheumatoid Arthritis clinical trial advancements @ Rheumatoid Arthritis Treatment Market

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Rheumatoid Arthritis Current Treatment Patterns

4. Rheumatoid Arthritis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Rheumatoid Arthritis Late Stage Products (Phase-III)

7. Rheumatoid Arthritis Mid-Stage Products (Phase-II)

8. Rheumatoid Arthritis Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Rheumatoid Arthritis Products

11. Dormant Rheumatoid Arthritis Products

12. Rheumatoid Arthritis Discontinued Products

13. Rheumatoid Arthritis Product Profiles

14. Key Companies in the Rheumatoid Arthritis Market

15. Key Products in the Rheumatoid Arthritis Therapeutics Segment

16. Dormant and Discontinued Products

17. Rheumatoid Arthritis Unmet Needs

18. Rheumatoid Arthritis Future Perspectives

19. Rheumatoid Arthritis Analyst Review

20. Appendix

21. Report Methodology

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Rheumatoid Arthritis Clinical Trials 2025: Medication, EMA, PMDA, FDA Approvals, Therapies, Treatment Market, MOA, ROA, and Companies by DelveInsight

“Melanoma Clinical Trials”

(Albany, USA) DelveInsight’s, “Melanoma Pipeline Insight 2025” report provides comprehensive insights about 150+ companies and 170+ pipeline drugs in Melanoma pipeline landscape. It covers the Melanoma Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Melanoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

The Melanoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The Melanoma Pipeline report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Explore our latest breakthroughs in Melanoma research. Learn more about our innovative pipeline today! @ Melanoma Pipeline and Drug Insights

Key Takeaways from the Melanoma Pipeline Report

• In July 2025, Iovance Biotherapeutics Inc. announced a study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who subsequently have a blinded independent central review- verified confirmed progressive disease (PD) will be offered lifileucel monotherapy in an optional crossover period.
• In June 2025, Merck Sharp & Dohme LLC announced a study is to learn if people who receive V940 with pembrolizumab live longer without the cancer growing or spreading than people who receive placebo with pembrolizumab. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of a study treatment.
• In June 2025, Hoffmann-La Roche conducted a study will evaluate the efficacy and safety in participants with metastatic melanoma who developed brain metastases. Participants may or may not have received prior systemic treatment for metastatic melanoma [except treatment with v-raf murine sarcoma viral oncogene homolog B (BRAF) or mitogen-activated protein kinase (MEK) inhibitors]. Participants will receive oral doses of 960 mg vemurafenib twice daily until disease progression, unacceptable toxicity or consent withdrawal.
• In June 2025, Iovance Biotherapeutics announced that the Journal of Clinical Oncology has published the final analysis from the Phase II C-144-01 clinical trial evaluating the individualized T cell therapy AMTAGVI in patients with advanced melanoma and was simultaneously presented during an oral session at the 2025 ASCO Annual Meeting.
• In June 2025, Replimune presented two posters highlighting the data updates for the IGNYTE Study of RP1 plus nivolumab in anti-PD1 failed melanoma at the 2025 ASCO annual meeting.
• In May 2025, Immatics announced the presentation of expanded data from the ongoing Phase Ib clinical trial evaluating IMA203 in heavily pretreated patients with metastatic melanoma
• In April 2025, IDEAYA Biosciences announced a successful FDA Type D meeting on the Phase III registrational trial design that would assess the safety and efficacy of darovasertib for potential regulatory approval as neoadjuvant therapy for primary uveal melanoma
• In February 2025, BMS announced that the Phase III RELATIVITY-098 trial evaluating OPDUALAG for the adjuvant treatment of patients with completely resected stage III–IV melanoma did not meet its primary endpoint of recurrence-free survival (RFS). The safety profile of OPDUALAG observed in this analysis was consistent with the known profiles of nivolumab and relatlimab.
• DelveInsight’s Melanoma pipeline report depicts a robust space with 150+ active players working to develop 170+ pipeline therapies for Melanoma treatment.
• The Food and Drug Administration (FDA)-approved therapies for melanoma include AMTAGVI (lifileucel, Iovance Biotherapeutics), OPDUALAG (nivolumab + relatlimab, Bristol Myers Squibb [BMS]), KEYTRUDA (pembrolizumab, Merck), OPDIVO (nivolumab, BMS), KIMMTRAK (tebentafusp-tebn, Immunocore), YERVOY (ipilimumab, BMS), TECENTRIQ (atezolizumab, Roche), and others.
• Melanoma became the first indication, where LAG3 (next generation immunotherapy) received regulatory nod from the US FDA. The FDA approved the combination of relatlimab (LAG3) and nivolumab (antiPD1), marketed as OPDUALAG.
• The leading Melanoma Companies such as IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, BioNTech SE, TILT Biotherapeutics LLC, Nykode Therapeutics, Achilles Therapeutics UK Limited, Evaxion Biotech, InxMed, AiVita Biomedical, Cytovation AS, Ono Pharmaceuticals, Neon Therapeutics, Iovance Biotherapeutics, and others.
• Promising Melanoma Therapies such as Ipilimumab, GM-CSF, Temozolomide, Tilsotolimod, Pembrolizumab, Lenvatinib, L19IL2 + L19TNF, and others.
• In 2024, the total number of incident cases of melanoma was approximately 105,050 in the US.

Stay informed about the cutting-edge advancements in Melanoma treatments. Download for updates and be a part of the revolution in cancer care @ Melanoma Clinical Trials and Recent Developments

Melanoma Emerging Drugs Profile

IO102 IO103: IO Biotech

IO102-IO103 is an investigational immune-modulating therapeutic cancer vaccine designed to target the immunosuppressive mechanisms mediated by the proteins indoleamine 2,3-dioxygenase (IDO) and programmed death-ligand 1 (PD-L1). IDO and/or PD-L1 are overexpressed by many types of solid tumors and immune-suppressive cells (Tregs and TAMs) in the TME. The company is developing this vaccine based on its T-win® vaccine platform. Currently it is in Phase III stage of clinical trial evaluation to treat Melanoma.

mRNA 4157: Moderna Inc.

mRNA-4157/V940 is a novel investigational messenger ribonucleic acid (mRNA)-based personalized cancer vaccine consisting of a single synthetic mRNA coding for up to 34 neoantigens that is designed to stimulate an immune response by generating specific T cell responses based on the unique mutational signature of a patient’s tumor. The drug is been developed jointly by Moderna & Merck. Currently being evaluated in the Phase III studies.

MK-4830: Merck Sharp & Dohme LLC

MK-4830 is an investigational monoclonal antibody that inhibits the binding of Immunoglobulin-like transcript 4 (ILT-4) to its ligands. The drug candidate is being developed in combination with KEYTRUDA. MK-4830 is being developed under an agreement with Agenus Inc. Currently the drug is being evaluated in Phase II for the treatment of Colorectal Cancer.

BNT111: BioNTech SE

BNT111 is an intravenous therapeutic cancer immunotherapy candidate encoding a fixed set of four cancer-specific antigens optimized for immunogenicity and delivered as RNA-lipoplex formulation. The drug induces novel antigen-specific anti-tumor immune responses and enhances pre-existing immune responses against the encoded melanoma-associated antigens. The drug is in Phase II stage of clinical trials.

TILT 123: TILT Biotherapeutics LLC

TILT-123 is a human 5/3 chimeric adenovirus that has been engineered to encode human Tumor Necrosis Factor alpha (hTNFa) and human Interleukin 2 (hIL-2) cytokines. It is optimized to generate an anti-cancer immune response by boosting the activity of T-cells and also stimulating other arms of the innate and adaptive immune system. TILT-123 can be administered by intravenous, intratumoral, intraperitoneal and intrapleural injection. The drug is in Phase I stage of clinical trials.

The Melanoma Pipeline report provides insights into

• The Melanoma pipeline report provides detailed insights about companies that are developing therapies for the treatment of Melanoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Melanoma Treatment.
• Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Melanoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Melanoma market.

Learn more about Melanoma Drugs opportunities in our groundbreaking Melanoma research and development projects @ Melanoma Medication and Unmet Needs

Melanoma Companies

IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, BioNTech SE, TILT Biotherapeutics LLC, Nykode Therapeutics, Achilles Therapeutics UK Limited, Evaxion Biotech, InxMed, AiVita Biomedical, Cytovation AS, Ono Pharmaceuticals, Neon Therapeutics, Iovance Biotherapeutics, and others.

Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical

Melanoma Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Discover the latest advancements in Melanoma treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Melanoma Market Drivers and Barriers, and Future Perspectives

Scope of the Melanoma Pipeline Report

• Coverage- Global
• Melanoma Companies- IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, BioNTech SE, TILT Biotherapeutics LLC, Nykode Therapeutics, Achilles Therapeutics UK Limited, Evaxion Biotech, InxMed, AiVita Biomedical, Cytovation AS, Ono Pharmaceuticals, Neon Therapeutics, Iovance Biotherapeutics, and others.
• Melanoma Therapies– Ipilimumab, GM-CSF, Temozolomide, Tilsotolimod, Pembrolizumab, Lenvatinib, L19IL2 + L19TNF, and others.
• Melanoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Melanoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Melanoma Pipeline on our website @ Melanoma Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. Melanoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Comparative Analysis
8. IO102 IO103 : IO Biotech
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. MK-4830: Merck Sharp & Dohme LLC
12. Early Stage Products (Phase I)
13. Comparative Analysis
14. TILT 123: TILT Biotherapeutics LLC
15. Inactive Products
16. Melanoma Key Companies
17. Melanoma Key Products
18. Melanoma- Unmet Needs
19. Melanoma- Market Drivers and Barriers
20. Melanoma- Future Perspectives and Conclusion
21. Melanoma Analyst Views
22. Melanoma Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Melanoma Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight

“Dystrophic Epidermolysis Bullosa Market”

(Albany, USA) DelveInsight’s “Dystrophic Epidermolysis Bullosa Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Dystrophic Epidermolysis Bullosa, historical and forecasted epidemiology as well as the Dystrophic Epidermolysis Bullosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Dystrophic Epidermolysis Bullosa market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Dystrophic Epidermolysis Bullosa market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Dystrophic Epidermolysis Bullosa treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Dystrophic Epidermolysis Bullosa market.

Request for free sample report @ Dystrophic Epidermolysis Bullosa Market Forecast

Key Takeaways from the Dystrophic Epidermolysis Bullosa Market Report

• According to DelveInsight’s analysis, the growth of the DEB market is expected to be mainly driven by increasing prevalence, patient awareness, label expansion of approved therapies, high cost of therapies, and robust clinical pipeline during the forecast period [2025–2034].
• DelveInsight estimates that the dystrophic epidermolysis bullosa market size in the 7MM is expected to grow from USD 550 million in 2023 at a significant CAGR by 2034.
• In July 2025, Krystal Biotech announced it is targeting first European launch of VYJUVEK in Germany in 3Q 2025 and France in 4Q 2025. The company also announced that the results of the open label extension (OLE) study of VYJUVEK in Japanese DEB patients was published in the Journal of Dermatology.
• In July 2025, StemRIM announced that patient enrollment for the additional Phase II clinical trial on Redasemtide, which was previously out-licensed to Shionogi for DEB has been completed
• In June 2025, Abeona Therapeutics announced publication of results from the pivotal Phase III VIITAL study (NCT04227106) evaluating the efficacy and safety of ZEVASKYN gene-modified cellular sheets, also known as pzcel, for the treatment of wounds in adult and pediatric patients with RDEB.
• In May 2025, RHEACELL announced that it has entered into an exclusive partnership agreement with the AOP Health Group, who will commercialize RHEACELL’s two stem cell products, EBESANAR and AMESANAR, in Europe, Turkey, Israel and the MENA region (Middle East and Northern Africa). RHEACELL retains full commercialization rights to EBESANAR and AMESANAR in other major markets, including North America, Asia-Pacific and Latin America, and will seek strategic distribution partners in those markets.
• In February 2025, Castle Creek Biosciences secured USD 75 million in financing to support a Phase III trial testing its gene therapy to promote wound healing in people with DEB. The royalty financing agreement for Castle Creek‘s treatment, D-Fi, was led by Ligand Pharmaceuticals, making a USD 50 million investment.
• In September 2024, FILSUVEZ, was approved for use in the UK by the National Institute for Health Care and Excellence (NICE) for the treatment of dystrophic EB (DEB) and junctional EB (JEB).
• As of 2023, according to DEBRA (a patient support organization for individuals with epidermolysis bullosa), approximately 25,000 people are living with epidermolysis bullosa in the US. This condition occurs in every racial and ethnic group and affects both genders equally.
• Epidermolysis bullosa is slightly more prevalent in males than females.
• The total prevalent population of DEB in the 7MM comprised ~14,400 cases in 2024. These cases are projected to Increase for the study period of 2020–2034.
• As per analysis, among the EU4 and the UK, the United Kingdom had the highest number of prevalent cases of DEB, i.e., ~1,700 in 2024, followed by Germany. On the other hand, France had the lowest prevalent population in 2024.

• As of now, only four therapies, namely FILSUVEZ (Chiesi Farmaceutici), VYJUVEK (Krystal Biotech), JACE (Japan Tissue Engineering), and recently approved ZEVASKYN (Abeona Therapeutics), have been approved for treating DEB, leaving a significant unmet need for effective and targeted dystrophic epidermolysis bullosa treatments.

• Globally, leading dystrophic epidermolysis bullosa companies such as Phoenix Tissue Repair, Castle Creek Biosciences, Phoenicis Therapeutics, Aegle Therapeutics, RHEACELL GmbH & Co. KG, Anterogen Co., Ltd., Abeona Therapeutics, Inc., InMed Pharmaceuticals, BridgeBio Inc., Eloxx Pharmaceuticals, Relief Therapeutics, Quoin Pharmaceuticals, among others are developing novel dystrophic epidermolysis bullosa drugs that can be available in the dystrophic epidermolysis bullosa market in the coming years.
• The promising dystrophic epidermolysis bullosa therapies in the pipeline include D-Fi (FCX-007), FCX-007, Oleogel-S10, VYJUVEK (beremagene geperpavec), FILSUVEZ (birch triterpenes), EB-101, PTR-01, RGN-137, INM-755, and others
• The current dystrophic epidermolysis bullosa diagnosis has improved in recent decades, leading to growing awareness, improved management, and better outcomes.
• There remains a significant unmet need for effective treatment of RDEB wounds, particularly those that are chronic and susceptible to infection. With a single surgical application, ZEVASKYN offers individuals with RDEB a promising solution, promoting wound healing and reducing pain, even in the most severe cases.

Discover which therapies are expected to grab the major dystrophic epidermolysis bullosa market share @ Dystrophic Epidermolysis Bullosa Treatment Market

Dystrophic Epidermolysis Bullosa Overview

Dystrophic epidermolysis bullosa (DEB) is one of the most frequent kinds of epidermolysis bullosa. Epidermolysis bullosa generates highly sensitive skin that blisters easily. Dystrophic epidermolysis bullosa is caused by alterations (mutations) in the COL7A1 gene and is inherited in an autosomal dominant or autosomal recessive way, depending on the subtype. Dystrophic epidermolysis bullosa causes are usually hereditary. The disease’s gene may have been passed down from one of the disease’s parents (autosomal dominant inheritance).

Based on this, Dystrophic epidermolysis bullosa is divided into Dominant DEB (DDEB-mild form) and Recessive DEB (RDEB- severe and incurable). Blisters, itchy, painful skin, dysphagia, dental issues, and others are the common dystrophic epidermolysis bullosa symptoms.

Dystrophic Epidermolysis Bullosa Epidemiology

Across the 7MM (excluding the US), recessive DEB (RDEB) was more common than dominant DEB (DDEB). The prevalent population of DEB in Japan was approximately 850 cases in 2024. These cases are anticipated to increase by 2034.

As per analysis, among the EU4 and the UK, the United Kingdom had the highest number of prevalent cases of DEB, i.e., ~1,700 in 2024, followed by Germany. On the other hand, France had the lowest prevalent population in 2024.

The dystrophic epidermolysis bullosa market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

• Diagnosed Prevalent Cases of Dystrophic Epidermolysis Bullosa (DEB)
• Age-specific Cases of Dystrophic Epidermolysis Bullosa (DEB)
• Type-specific Cases of Dystrophic Epidermolysis Bullosa (DEB)
• Severity-specific Cases of Dystrophic Epidermolysis Bullosa (DEB)

Download the report to understand which factors are driving dystrophic epidermolysis bullosa epidemiology trends @ Dystrophic Epidermolysis Bullosa Prevalence

Dystrophic Epidermolysis Bullosa Treatment Market

The current dystrophic epidermolysis bullosa treatment comprises contemporary wound care as well as the removal of external factors that induce blistering and impede wound healing. Proper skin care necessitates strict personal hygiene and thorough moisturizing dystrophic epidermolysis bullosa therapy. Blisters that do not cause further damage or infection heal well with regular skincare and hygiene. Today’s aqueous disinfectants are very effective and easy to apply. Adhesives and compressive dressings should be avoided since they stimulate the production of new blisters. Silicon-based, slightly adherent wound care dystrophic epidermolysis bullosa therapies have proven to be highly useful, particularly for tough skin areas such as the elbows, shoulders, and trunk.

Moreover, currently, there are no approved therapies for dystrophic epidermolysis bullosa treatment. The current dystrophic epidermolysis bullosa treatment just alleviates symptoms; it does not provide a long-term cure. As a result, there is an urgent need for more effective and personalized therapies with improved long-term side effect profiles.

Stem cell-based therapies are becoming increasingly important, especially for previously incurable diseases. Due to the special immunomodulatory and anti-inflammatory properties, ABCB5+ mesenchymal stromal cells (ABCB5+ MSCs) represent a new, promising therapeutic approach for various chronic inflammatory diseases, including epidermolysis bullosa.

Gene therapies for epidermolysis bullosa are becoming a reality with the approval of VYJUVEK, the first FDA approved topical gene therapy.

The high costs associated with developing treatments for rare diseases like epidermolysis bullosa may limit access to treatment for many patients, which can hamper the uptake of innovative therapies. Obtaining adequate reimbursement from healthcare payers can be challenging for novel therapies, impacting their adoption and patient access.

To know more about dystrophic epidermolysis bullosa treatment options, visit @ Dystrophic Epidermolysis Bullosa Companies and FDA Approvals

Dystrophic Epidermolysis Bullosa Pipeline Therapies and Key Companies

• FCX-007: Castle Creek Biosciences
• Oleogel-S10: Amryth Pharma
• Beremagene Geperpavec: Krystal Biotech
• EB-101: Abeona Therapeutics
• PTR-01: BridgeBio/Phoenix Tissue Repair
• RGN-137: Lenus Therapeutics
• INM-755: InMed Pharmaceuticals

Dystrophic Epidermolysis Bullosa Market Dynamics

The dystrophic epidermolysis bullosa market is expected to show positive growth in the coming years. As there is no approved dystrophic epidermolysis bullosa treatment, so developing therapies is a viable option. The extensive clinical dystrophic epidermolysis bullosa pipeline, which includes innovative RoA and MoA medicines, shows promise for the future dystrophic epidermolysis bullosa market.

Furthermore, patients’ willingness to pay for expensive treatments such as gene therapy, cell-based therapy, and molecular therapy to treat the disease is increasing, which is driving the dystrophic epidermolysis bullosa market. Additionally, the widespread dystrophic epidermolysis bullosa prevalence is also a prominent factor bolstering the dystrophic epidermolysis bullosa market.

However, certain factors impede the expansion of the dystrophic epidermolysis bullosa market. Improving QOL and wound care can be costly, and healthcare insurance may not cover the costs. Furthermore, several countries lack a patient registration system for epidermolysis bullosa. Moreover, despite increasing improvements in gene and cell therapies for dystrophic epidermolysis bullosa, a lack of awareness of the condition may hinder the growth of the DEB care and dystrophic epidermolysis bullosa market. Furthermore, gene therapy is costly; also, most countries’ healthcare systems, including the United States’, are not geared to manage large one-time expenses.

Therefore, the above-mentioned aspects are likely to hamper the growth of the dystrophic epidermolysis bullosa market in the future.

Scope of the Dystrophic Epidermolysis Bullosa Market Report

• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Dystrophic Epidermolysis Bullosa Market Size in 2023: ~USD 550 Million
• Key Dystrophic Epidermolysis Bullosa Companies: Phoenix Tissue Repair, Castle Creek Biosciences, Phoenicis Therapeutics, Aegle Therapeutics, RHEACELL GmbH & Co. KG, Anterogen Co., Ltd., Abeona Therapeutics, Inc., InMed Pharmaceuticals, BridgeBio Inc., Eloxx Pharmaceuticals, Relief Therapeutics, Quoin Pharmaceuticals, among others.
• Key Dystrophic Epidermolysis Bullosa Therapies: D-Fi (FCX-007), FCX-007, Oleogel-S10, VYJUVEK (beremagene geperpavec), FILSUVEZ (birch triterpenes), EB-101, PTR-01, RGN-137, INM-755, and others
• Therapeutic Assessment: Dystrophic Epidermolysis Bullosa current marketed and emerging therapies
• Dystrophic Epidermolysis Bullosa Market Dynamics: Dystrophic Epidermolysis Bullosa market drivers and barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Dystrophic Epidermolysis Bullosa Market Access and Reimbursement

Discover more about drugs for dystrophic epidermolysis bullosa in development @ Dystrophic Epidermolysis Bullosa Clinical Trials and Medications

Table of Contents

1. Dystrophic Epidermolysis Bullosa Market Key Insights

2. Dystrophic Epidermolysis Bullosa Market Report Introduction

3. Dystrophic Epidermolysis Bullosa Market Overview at a Glance

4. Dystrophic Epidermolysis Bullosa Market Executive Summary

5. Disease Background and Overview

6. Dystrophic Epidermolysis Bullosa Treatment and Management

7. Dystrophic Epidermolysis Bullosa Epidemiology and Patient Population

8. Patient Journey

9. Dystrophic Epidermolysis Bullosa Emerging Drugs

10. Seven Major Dystrophic Epidermolysis Bullosa Market Analysis

11. Dystrophic Epidermolysis Bullosa Market Outlook

12. Potential of Current and Emerging Therapies

13. KOL Views

14. Dystrophic Epidermolysis Bullosa Market Drivers

15. Dystrophic Epidermolysis Bullosa Market Barriers

16. Unmet Needs

17. SWOT Analysis

18. Appendix

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dystrophic Epidermolysis Bullosa Market Forecast 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, Therapies, and Companies by DelveInsight

“Hidradenitis Suppurativa Market”

(Albany, USA) DelveInsight’s “Hidradenitis Suppurativa Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Hidradenitis Suppurativa, historical and forecasted epidemiology as well as the Hidradenitis Suppurativa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Hidradenitis Suppurativa market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Hidradenitis Suppurativa market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Hidradenitis Suppurativa treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Hidradenitis Suppurativa market.

Uncover key insights into the evolving Hidradenitis Suppurativa market—track emerging therapies, forecast trends, and identify untapped opportunities across the 7MM @ Hidradenitis Suppurativa Market Forecast and Drugs Market

Some facts of the Hidradenitis Suppurativa Market Report are:

• According to DelveInsight, Hidradenitis Suppurativa market size is expected to grow at a decent CAGR by 2034.
• In July 2025, Novartis announced results of a Randomized, Double-blind, Double-dummy, Placebo-controlled, Multicenter, Phase 3 Study Assessing the Efficacy, Safety, and Tolerability of 2 Doses of Remibrutinib Over a 68-week Treatment Period in Adult Patients With Moderate to Severe Hidradenitis Suppurativa
• In July 2025, Avalo Therapeutics, Inc announced results of a Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa (LOTUS)
• In July 2025, Incyte Corporation announced results of a Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
• In December 2024:- UCB Biopharma SRL- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa. The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS).
• Leading Hidradenitis Suppurativa companies working in the market are Inflarx, Novartis Pharmaceuticals, Incyte Corporation, UCB Biopharma, Janssen Pharmaceuticals, Novartis Pharmaceuticals, Amgen, Chemocentryx, Priovant Therapeutics, Pfizer, Anaptysbio, Abbvie, Acelyrin, Aclaris Therapeutics, Boehringer Ingelheim, Eli Lilly, Moonlake Immunotherapeutics, Aristea Therapeutics, among others.
• Key Hidradenitis Suppurativa Therapies expected to launch in the market are HUMIRA, COSENTYX (secukinumab), BIMZELX (bimekizumab), and others.
• On February 2024, UCB Pharma announced results of a Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
• On March 2024, ACELYRIN Inc announced results of a Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Moderate to Severe Hidradenitis Suppurativa.
• On February 2024, Novartis announced results of a Long Term observAtional, Prospective, Multicenter Study to Collect iN a Real-world populatIon Data on the treatMent Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) (ANIMA).
• On February 2024, Eli Lilly and Company announced results of a Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Eltrekibart in Adult Participants With Moderate to Severe Hidradenitis Suppurativa.
• On March 2024, AbbVie announced a Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy.

Hidradenitis Suppurativa Overview

Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by painful, recurrent abscesses, nodules, and tunnels in areas rich in apocrine glands, such as the armpits, groin, and buttocks. The exact cause of Hidradenitis suppurativa is not fully understood but likely involves a combination of genetic predisposition, immune dysregulation, and environmental factors. Hidradenitis suppurativa can significantly impact quality of life due to pain, discomfort, and social stigma associated with the visible lesions. Diagnosis is based on clinical presentation and may require histopathological examination to confirm. Hidradenitis suppurativa Treatment strategies aim to alleviate symptoms, prevent new lesions, and improve overall well-being. Options include topical and systemic antibiotics, anti-inflammatory medications, immunosuppressants, and biologic therapies, surgical interventions such as drainage and excision, and lifestyle modifications. Multidisciplinary care involving dermatologists, surgeons, and other specialists is often necessary to manage HS effectively and address the diverse needs of affected individuals.

Learn more about Hidradenitis Suppurativa treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Hidradenitis Suppurativa Treatment Market

Hidradenitis Suppurativa Market

The Hidradenitis Suppurativa market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Hidradenitis Suppurativa market trends by analyzing the impact of current Hidradenitis Suppurativa therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Hidradenitis Suppurativa market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Hidradenitis Suppurativa market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

The primary approach to treating mild cases of the condition typically involves cleansing with antibacterial solutions and applying topical antibiotics. In instances of sudden exacerbation, healthcare providers may employ corticosteroid injections directly into affected areas and/or minor surgical interventions. For individuals with mild to moderate symptoms, oral treatments may include prolonged courses of broad-spectrum antibiotics and systemic retinoids. Presently, the market largely relies on medications prescribed off-label and HUMIRA, which stands as the sole officially approved therapy for hidradenitis suppurativa thus far.

The Hidradenitis Suppurativa (HS) market is driven by increasing disease awareness, rising prevalence, and advancements in biologic therapies such as HUMIRA, COSENTYX, and BIMZELX. Ongoing clinical trials exploring novel targets like IL-17, JAK, and PDE4 further support market growth. Additionally, strong pipeline activity and favorable regulatory support enhance the treatment landscape. However, the market faces barriers such as high treatment costs, limited approved therapies for mild cases, diagnostic delays, and poor patient adherence due to chronicity and recurrence. Moreover, competition from biosimilars and uncertainty in long-term efficacy of newer therapies may hinder widespread adoption and market expansion.

Hidradenitis Suppurativa Epidemiology

The Hidradenitis Suppurativa epidemiology section provides insights into the historical and current Hidradenitis Suppurativa patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Hidradenitis Suppurativa market report also provides the diagnosed patient pool, trends, and assumptions.

Hidradenitis suppurativa In 2020, the total prevalent cases of Hidradenitis Suppurativa were approximately 2.8 million cases in the US, which is expected to grow during the study period, i.e., 2020–2034.

Explore more about Hidradenitis Suppurativa Epidemiology @ Hidradenitis Suppurativa Prevalence

Hidradenitis Suppurativa Drugs Uptake

This section focuses on the uptake rate of the potential Hidradenitis Suppurativa drugs recently launched in the Hidradenitis Suppurativa market or expected to be launched in 2020-2034. The analysis covers the Hidradenitis Suppurativa market uptake by drugs, patient uptake by therapies, and sales of each drug.

Hidradenitis Suppurativa Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Hidradenitis Suppurativa market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Hidradenitis Suppurativa Pipeline Development Activities

The Hidradenitis Suppurativa report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Hidradenitis Suppurativa key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Hidradenitis Suppurativa pipeline development activities @ Hidradenitis Suppurativa Medication and FDA Approvals

Hidradenitis Suppurativa Therapeutics Assessment

Major key companies are working proactively in the Hidradenitis Suppurativa Therapeutics market to develop novel therapies which will drive the Hidradenitis Suppurativa treatment markets in the upcoming years are Inflarx, Novartis Pharmaceuticals, Incyte Corporation, UCB Biopharma, Janssen Pharmaceuticals, Novartis Pharmaceuticals, Amgen, Chemocentryx, Priovant Therapeutics, Pfizer, Anaptysbio, Abbvie, Acelyrin, Aclaris Therapeutics, Boehringer Ingelheim, Eli Lilly, Moonlake Immunotherapeutics, Aristea Therapeutics, among others

Learn more about the emerging Hidradenitis Suppurativa therapies & key companies @ Hidradenitis Suppurativa Clinical Trials and Recent Developments

Hidradenitis Suppurativa Report Key Insights

1. Hidradenitis Suppurativa Patient Population

2. Hidradenitis Suppurativa Market Size and Trends

3. Key Cross Competition in the Hidradenitis Suppurativa Market

4. Hidradenitis Suppurativa Market Dynamics (Key Drivers and Barriers)

5. Hidradenitis Suppurativa Market Opportunities

6. Hidradenitis Suppurativa Therapeutic Approaches

7. Hidradenitis Suppurativa Pipeline Analysis

8. Hidradenitis Suppurativa Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Hidradenitis Suppurativa Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Hidradenitis Suppurativa Competitive Intelligence Analysis

4. Hidradenitis Suppurativa Market Overview at a Glance

5. Hidradenitis Suppurativa Disease Background and Overview

6. Hidradenitis Suppurativa Patient Journey

7. Hidradenitis Suppurativa Epidemiology and Patient Population

8. Hidradenitis Suppurativa Treatment Algorithm, Current Treatment, and Medical Practices

9. Hidradenitis Suppurativa Unmet Needs

10. Key Endpoints of Hidradenitis Suppurativa Treatment

11. Hidradenitis Suppurativa Marketed Products

12. Hidradenitis Suppurativa Emerging Therapies

13. Hidradenitis Suppurativa Seven Major Market Analysis

14. Attribute Analysis

15. Hidradenitis Suppurativa Market Outlook (7 major markets)

16. Hidradenitis Suppurativa Access and Reimbursement Overview

17. KOL Views on the Hidradenitis Suppurativa Market

18. Hidradenitis Suppurativa Market Drivers

19. Hidradenitis Suppurativa Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hidradenitis Suppurativa Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, Therapies, and Companies by DelveInsight